Issued: 29 November 2018, London UK - LSE Announcement
GSK - Update on Strategic Review of Horlicks
As disclosed previously, in March 2018, GlaxoSmithKline Plc ("GSK") announced a strategic review of Horlicks and its other consumer healthcare nutrition products. The majority of Horlicks and other GSK nutrition products sales are generated in India by GlaxoSmithKline Consumer Healthcare Limited (the "GSKCH"). In response to recent press speculation, GSK confirms that consideration is being given to a potential transaction that includes a merger of GSKCH. There can be no assurance that a transaction will result from the review process or the evaluation of this option nor has any decision on the matter been made by the Company.
GSK enquiries: |
|
|
|
UK Media enquiries: |
Simon Steel |
+44 (0) 20 8047 5502 |
(London) |
|
|
|
|
US Media enquiries: |
Sarah Spencer |
+1 267 253 7349 |
(North Carolina) |
|
|
|
|
|
|
|
|
Analyst/Investor enquiries: |
Sarah Elton-Farr |
+44 (0) 20 8047 5194 |
(London) |
|
James Dodwell |
+44 (0) 20 8047 2406 |
(London) |
|
Danielle Smith |
+44 (0) 20 8047 7562 |
(London) |
|
Jeff McLaughlin |
+1 215 751 7002 |
(Philadelphia) |
|
|
|
|
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017. |
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
